Skip to content

Adaptive Biotechnologies

US · ADPT #2184 by market cap Listed 2019
27.93 -0.12 -0.43%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $27.5
    Market Newswire · 2026/11/5
  • Rating change
    Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $22
    Market Newswire · 2026/6/29
  • Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/11/10
  • J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/11/9
  • Rating change
    Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $27
    Market Newswire · 2026/10/13
  • Rating change
    William Blair Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
    Market Newswire · 2026/6/17
  • Rating change
    TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $32
    Market Newswire · 2026/10/13
  • Rating change
    Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Raises Target Price to $27
    Market Newswire · 2026/10/12
  • BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/11/6
  • Rating change
    Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $27.5
    Market Newswire · 2026/8/4
  • Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34
    Market Newswire · 2026/11/10
  • Rating change
    A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $25 to $28
    Market Newswire · 2026/7/31
  • Rating change
    Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $32
    Market Newswire · 2026/10/1
  • Rating change
    BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34
    Market Newswire · 2026/9/22
  • Rating change
    Goldman Sachs Initiates Adaptive Biotechnologies(ADPT.US) With Buy Rating, Announces Target Price $35
    Market Newswire · 2026/9/29
  • TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34
    Market Newswire · 2026/11/5
  • Rating change
    BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $24
    Market Newswire · 2026/7/23
  • Rating change
    J.P. Morgan Initiates Adaptive Biotechnologies(ADPT.US) With Buy Rating, Announces Target Price $30
    Market Newswire · 2026/10/14
  • Rating change
    TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/7/15
  • Rating change
    Craig-Hallum Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
    Market Newswire · 2026/9/18
  • Rating change
    Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Cuts Target Price to $13.54
    Market Newswire · 2026/5/12
  • Rating change
    Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/5/12
  • Rating change
    Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $27.5
    Market Newswire · 2026/8/24
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)
    TipRanks · 2026/5/12
  • BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/9/22

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adaptive Biotechnologies discussion 0 comments

Add a comment